nach oben

Clinical Rheumatology

Erschienen in:

01.05.2012 | Original Article

Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study

verfasst von: G. A. Hooisma, H. Balink, P. M. Houtman, R. H. J. A. Slart, K. D. F. Lensen

Erschienen in: Clinical Rheumatology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to identify clinical and laboratory parameters that may improve the effectiveness of the use of fluorodeoxyglucose positron emission tomography (¹⁸ F-FDG PET)(/CT) for diagnosing large vessel vasculitis (LVV), and secondarily to assess the contribution of ¹⁸ F-FDG PET/CT in finding other diagnoses for patients without signs of LVV on the scan. A multicenter retrospective study of ¹⁸ F-FDG PET(/CT) scans performed between January 2000 and December 2009 for clinical suspicion of LVV was conducted. A total of 304 ¹⁸ F-FDG PET(/CT) scans were included, of which 62 (20%) were positive and 242 (80%) were negative for LVV. Univariate analysis showed that patients with a positive scan were older (65.9 ± 13.4 versus 58.6 ± 16.5 years, p = 0.002), were more frequently female (76% versus 55%, p = 0.002), more often had a history of temporal arteritis (10% versus 3%, p = 0.044), less frequently had artralgia (31% versus 67%, p = 0.000), and had higher thrombocyte counts (434 ± 161 versus 373 ± 168 × 10⁹/l, p = 0.049) and a higher erythrocyte sedimentation rate (ESR) (72.6 ± 31.0 versus 51.4 ± 30.5 mm/h, p = 0.001) than patients with a negative scan. In the multivariate analysis, only artralgia (OR 0.091; 95% CI 0.023–0.366) and ESR (OR 1.024; 95% CI 1.002–1.046) remained statistically significant predictors. The presence of artralgia is a statistically significant negative predictor and an elevated ESR a statistically significant positive predictor of LVV showing up on ¹⁸ F-FDG PET(/CT). A reliable prediction of the outcome of the scan, based on these two parameters, is not possible however. ¹⁸ F-FDG PET(/CT) allows early diagnosis of LVV and may discover occult inflammatory or neoplastic disorders.

Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192PubMedCrossRef

Gornik HL, Creager MA (2008) Aortitis. Circulation 117:3039–3051PubMedCrossRef

Levine SM, Hellmann DB (2002) Giant cell arteritis. Curr Opin Rheumatol 14:3–10PubMedCrossRef

Walter MA (2007) [(18)F]fluorodeoxyglucose PET in large vessel vasculitis. Radiol Clin North Am 45:735–744, viiiPubMedCrossRef

Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372:234–245PubMedCrossRef

Bongartz T, Matteson EL (2006) Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 18:10–17PubMedCrossRef

Janssen SP, Comans EH, Voskuyl AE, Wisselink W, Smulders YM (2008) Giant cell arteritis: heterogeneity in clinical presentation and imaging results. J Vasc Surg 48:1025–1031PubMedCrossRef

Cantini F, Niccoli L, Storri L et al (2004) Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 33:294–301PubMedCrossRef

Blockmans D, Stroobants S, Maes A, Mortelmans L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108:246–249PubMedCrossRef

10.

Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P (2001) Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 30:249–256PubMedCrossRef

11.

Mari B, Monteagudo M, Bustamante E et al (2009) Analysis of temporal artery biopsies in an 18-year period at a community hospital. Eur J Intern Med 20:533–536PubMedCrossRef

12.

Taylor-Gjevre R, Vo M, Shukla D, Resch L (2005) Temporal artery biopsy for giant cell arteritis. J Rheumatol 32:1279–1282PubMed

13.

Chong EW, Robertson AJ (2005) Is temporal artery biopsy a worthwhile procedure? ANZ J Surg 75:388–391PubMedCrossRef

14.

Hayreh SS, Podhajsky PA, Raman R, Zimmerman B (1997) Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 123:285–296PubMed

15.

Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2009) Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 88:221–226CrossRef

16.

Park MC, Lee SW, Park YB, Chung NS, Lee SK (2005) Clinical characteristics and outcomes of Takayasu’s arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 34:284–292PubMedCrossRef

17.

Mwipatayi BP, Jeffery PC, Beningfield SJ et al (2005) Takayasu arteritis: clinical features and management: report of 272 cases. ANZ J Surg 75:110–117PubMedCrossRef

18.

Kissin EY, Merkel PA (2004) Diagnostic imaging in Takayasu arteritis. Curr Opin Rheumatol 16:31–37PubMedCrossRef

19.

Ahmadi-Simab K, Hellmich B, Holl-Ulrich K, Fleischmann C, Dourvos O, Gross WL (2007) Acute coronary syndrome in Takayasu arteritis without elevation of acute phase parameters. Rheumatology (Oxford) 46:554–555CrossRef

20.

Hoffman GS, Ahmed AE (1998) Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 66(Suppl 1):S191–S194PubMedCrossRef

21.

Andrews J, Mason JC (2007) Takayasu’s arteritis—recent advances in imaging offer promise. Rheumatology (Oxford) 46:6–15CrossRef

22.

Bartels AL, Zeebregts CJ, Bijl M, Tio RA, Slart RH (2009) Fused FDG-PET and MRI imaging of Takayasu arteritis in vertebral arteries. Ann Nucl Med 23:753–756PubMedCrossRef

23.

Meave A, Soto ME, Reyes PA et al (2007) Pre-pulseless Takayasu’s arteritis evaluated with 18F-FDG positron emission tomography and gadolinium-enhanced magnetic resonance angiography. Tex Heart Inst J 34:466–469PubMed

24.

Kaku B, Higuchi T, Kanaya H et al (2006) Usefulness of fluorine-18-fluorodeoxyglucose positron emission tomography in a patient with Takayasu’s arteritis associated with antiphospholipid syndrome. Int Heart J 47:311–317PubMedCrossRef

25.

Weaver FA, Kumar SR, Yellin AE et al (2004) Renal revascularization in Takayasu arteritis-induced renal artery stenosis. J Vasc Surg 39:749–757PubMedCrossRef

26.

Henes JC, Muller M, Krieger J et al (2008) [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. Clin Exp Rheumatol 26:S47–S52PubMed

27.

Meller J, Strutz F, Siefker U et al (2003) Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 30:730–736PubMedCrossRef

28.

Meller J, Grabbe E, Becker W, Vosshenrich R (2003) Value of F-18 FDG hybrid camera PET and MRI in early Takayasu aortitis. Eur Radiol 13:400–405PubMed

29.

Blockmans D, Bley T, Schmidt W (2009) Imaging for large-vessel vasculitis. Curr Opin Rheumatol 21:19–28PubMedCrossRef

30.

Pipitone N, Versari A, Salvarani C (2008) Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford) 47:403–408CrossRef

31.

Zerizer I, Tan K, Khan S et al (2010) Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis. Eur J Radiol 73:504–509PubMedCrossRef

32.

Kobayashi Y, Ishii K, Oda K et al (2005) Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 46:917–922PubMed

33.

Ell PJ (2006) The contribution of PET/CT to improved patient management. Br J Radiol 79:32–36PubMedCrossRef

34.

Hautzel H, Sander O, Heinzel A, Schneider M, Muller HW (2008) Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med 49:1107–1113PubMedCrossRef

35.

Dunphy MP, Freiman A, Larson SM, Strauss HW (2005) Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med 46:1278–1284PubMed

36.

Besson FL, Parienti JJ, Bienvenu B et al (2011) Diagnostic performance of (18)F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 38:1764–1772PubMedCrossRef

37.

Balink H, Bruyn GA (2007) The role of PET/CT in Cogan’s syndrome. Clin Rheumatol 26:2177–2179PubMedCrossRef

38.

Dasgupta B (2010) Concise guidance: diagnosis and management of giant cell arteritis. Clin Med 10:381–386PubMed

39.

Ezeonyeji AN, Borg FA, Dasgupta B (2011) Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol 30:259–262PubMedCrossRef

40.

Mukhtyar C, Guillevin L, Cid MC et al (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318–323PubMedCrossRef

41.

Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A (2008) Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford) 47:96–101CrossRef

42.

Moosig F, Czech N, Mehl C et al (2004) Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 63:870–873PubMedCrossRef

43.

Arnaud L, Haroche J, Malek Z et al (2009) Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 60:1193–1200PubMedCrossRef

44.

Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ (1997) Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40:19–26PubMedCrossRef

45.

Weyand CM, Hicok KC, Hunder GG, Goronzy JJ (1994) Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121:484–491PubMed

46.

Blockmans D, De CL, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H (2007) Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 46:672–677CrossRef

47.

Blockmans D, Maes A, Stroobants S et al (1999) New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38:444–447CrossRef

48.

Hamrin B, Jonsson N, Hellsten S (1968) “Polymyalgia arteritica”. Further clinical and histopathological studies with a report of six autopsy cases. Ann Rheum Dis 27:397–405PubMedCrossRef

49.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL (2003) Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 48:3522–3531PubMedCrossRef

50.

Taniguchi Y, Arii K, Kumon Y et al (2010) Positron emission tomography/computed tomography: a clinical tool for evaluation of enthesitis in patients with spondyloarthritides. Rheumatology (Oxford) 49:348–354CrossRef

51.

Toriihara A, Seto Y, Yoshida K et al (2009) F-18 FDG PET/CT of polymyalgia rheumatica. Clin Nucl Med 34:305–306PubMedCrossRef

52.

Blockmans D, Coudyzer W, Vanderschueren S et al (2008) Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 47:1179–1184CrossRef

53.

Vanderschueren S, Del BE, Ruttens D, Van B, I, Wauters E, Knockaert DD (2009) Inflammation of unknown origin versus fever of unknown origin: two of a kind. Eur J Intern Med 20: 415–8

54.

Bleeker-Rovers CP, Vos FJ, Mudde AH et al (2007) A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 34:694–703PubMedCrossRef

55.

Blockmans D, Knockaert D, Maes A et al (2001) Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 32:191–196PubMedCrossRef

56.

Buysschaert I, Vanderschueren S, Blockmans D, Mortelmans L, Knockaert D (2004) Contribution of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever of unknown origin. Eur J Intern Med 15:151–156PubMedCrossRef

57.

Balink H, Collins J, Bruyn G, Gemmel F (2009) F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med 34:862–868PubMedCrossRef

58.

Meller J, Sahlmann CO, Gurocak O, Liersch T, Meller B (2009) FDG-PET in patients with fever of unknown origin: the importance of diagnosing large vessel vasculitis. Q J Nucl Med Mol Imaging 53:51–63PubMed

Titel: Parameters related to a positive test result for FDG PET(/CT) for large vessel vasculitis: a multicenter retrospective study
verfasst von: G. A. Hooisma
H. Balink
P. M. Houtman
R. H. J. A. Slart
K. D. F. Lensen
Publikationsdatum: 01.05.2012
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 5/2012
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-012-1945-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome

Physical therapy, corticosteroid injection, and extracorporeal shock wave treatment in lateral epicondylitis

The role of regulatory T cells in familial Mediterranean fever (FMF)

A modified juvenile arthritis damage index to improve articular damage assessment in juvenile idiopathic arthritis—enthesitis-related arthritis (JIA-ERA)

Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus

QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients